Nebraska Cancer Specialists

Phase II Study of Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous Cell Carcinoma: Final Analysis

We previously reported the results of a multicenter phase II trial (ClinicalTrials.gov identifier: NCT04154943 ) of neoadjuvant cemiplimab in resectable stage II to IV cutaneous squamous cell carcinoma (CSCC), in which the pathologic complete response (pCR) rate was 51%. At the 1...